| 1.64 0.16 (10.81%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.66 | 1-year : | 3.35 |
| Resists | First : | 2.28 | Second : | 2.87 |
| Pivot price | 1.63 |
|||
| Supports | First : | 1.32 | Second : | 1.09 |
| MAs | MA(5) : | 1.53 |
MA(20) : | 1.65  |
| MA(100) : | 2.91 |
MA(250) : | 3.54 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 36.2 |
D(3) : | 31.6 |
| RSI | RSI(14): 44 |
|||
| 52-week | High : | 7.66 | Low : | 1.32 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MGRX ] has closed below upper band by 49.4%. Bollinger Bands are 66.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.68 - 1.69 | 1.69 - 1.69 |
| Low: | 1.44 - 1.45 | 1.45 - 1.46 |
| Close: | 1.63 - 1.64 | 1.64 - 1.65 |
Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
Thu, 15 May 2025
MANGOCEUTICALS, INC. SEC 10-Q Report - TradingView
Fri, 25 Apr 2025
MangoRx Targets $37B Pouch Industry: Acquires Smokeless Tech IP, Lands Former JUUL President - Stock Titan
Fri, 25 Apr 2025
Mangoceuticals Announces Strategic Entry into High Growth - GlobeNewswire
Tue, 22 Apr 2025
Mangoceuticals Disrupts $33B Health Market: 5 Revolutionary Products Including FDA-Approved Treatments - Stock Titan
Tue, 25 Mar 2025
Major Diabetes Market Breakthrough: Mangoceuticals Launches GLP-1 Alternative at Fraction of Cost - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.63e+006 (%) |
| Held by Institutions | 17.2 (%) |
| Shares Short | 245 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.51e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 264.6 % |
| Return on Equity (ttm) | -62.8 % |
| Qtrly Rev. Growth | 615870 % |
| Gross Profit (p.s.) | -23.14 |
| Sales Per Share | -48.1 |
| EBITDA (p.s.) | 154455 |
| Qtrly Earnings Growth | -4.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 0.93 |
| Dividend | 0 |
| Forward Dividend | 277450 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|